In this episode of MedOncNow, Dr. Aly-Khan Lalani, walks us through the rapidly evolving landscape of perioperative therapy for muscle-invasive bladder cancer — two practice-changing trials, two different patient populations, and a whole lot of practical decisions that no algorithm will make for you. This is particularly timely given there is an access program for this Regimen.

In this episode, Dr. Howard Lim takes us through the peri-operative management of Gastric/GEJ Adenocarcinoma. This is particularly timely given Ontario now has funded access to the Matterhorn regimen, with the hopes of other provinces to follow.

In this episode, Dr. Aalok Kumar takes us through the practical aspects of choosing between the available adjuvant intensification options in "High Risk" HR+, HER2 - Early Breast Cancer. This is timely given there is public funding for Abemaciclib and PSP support for Ribociclib.

In this episode, Dr. Arndt Vogel takes us through targeted therapy in Biliary Tract Cancers. As we now have access to Pemigatinib (PART 1) to target FGFR2 fusions and Ivosidenib (PART 2) for IDH1 mutated cholangiocarcinoma, I thought it important to discuss how to incorporate these into practice.

In this episode, Dr. Arndt Vogel takes us through targeted therapy in Biliary Tract Cancers. As we now have access to Pemigatinib to target FGFR2 fusions and Ivosidenib for IDH1 mutated cholangiocarcinoma, I thought it important to discuss how to incorporate these into practice.

In this episode, Dr. Urvi Shah takes us through how to optimize diet in cancer treatment and prevention.

In this episode, Dr. Scott Berry takes us through practical discussions on sequencing the increasing available treatment options for Advanced Colorectal cancer.

As we now access Encorafenib + Cetuximab + Folfox via a Pfizer sponsored PSP for the he first line treatment Braf V600e mutated, RAS wt, dMMR/MSS metastatic Colorectal cancer, Dr. Rachel Goodwin takes us through the regimen, its practical use and efficacy and toxicity management.